Reduction of Fas/CD95 promoter methylation, upregulation of fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-Cell lymphoma

Archives of Dermatology

Volumn 147, Issue 4, 2011, Pages 443-449

  Wu, Jianqiang ^a   Wood, Gary S ^a  

^a UNIVERSITY OF WISCONSIN MADISON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; AZACITIDINE; FAS ANTIGEN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; METHOTREXATE;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DNA METHYLATION; DRUG SENSITIVITY; DRUG TARGETING; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN LOCALIZATION; TRANSCRIPTION REGULATION; UPREGULATION;

ANTIGENS, CD95; ANTINEOPLASTIC AGENTS; APOPTOSIS; AZACITIDINE; CELL LINE, TUMOR; DNA METHYLATION; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; INTERFERON TYPE I, RECOMBINANT; LYMPHOMA, T-CELL, CUTANEOUS; METHOTREXATE; NF-KAPPA B; PROMOTER REGIONS, GENETIC; SKIN NEOPLASMS; UP-REGULATION;

EID: 79953840339     PISSN: 0003987X     EISSN: 15383652     Source Type: Journal    
DOI: 10.1001/archdermatol.2010.376     Document Type: Article

References (30)

1. Olsen E, Vonderheid E, Pimpinelli N, et al; ISCL/EORTC. Revisions to the staging and classification of mycosis fungoides and Sézary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC). Blood. 2007;110(6):1713-1722.
2. Wu J, Nihal M, Siddiqui J, Vonderheid EC, Wood GS. Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation. J Invest Dermatol. 2009;129(5):1165-1173.
3. Meech SJ, Edelson R, Walsh P, Norris DA, Duke RC. Reversible resistance to apoptosis in cutaneous T cell lymphoma. Ann N Y Acad Sci. 2001;941(9): 46-58. (Pubitemid 32928333)
4. Ni X, Zhang C, Talpur R, Duvic M. Resistance to activation-induced cell death and bystander cytotoxicity via the Fas/Fas ligand pathway are implicated in the pathogenesis of cutaneous T cell lymphomas. J Invest Dermatol. 2005;124(4):741-750. (Pubitemid 40489501)
5. Braun FK, Fecker LF, Schwarz C, et al. Blockade of death receptor-mediated pathways early in the signaling cascade coincides with distinct apoptosis resistance in cutaneous T-cell lymphoma cells. J Invest Dermatol. 2007;127(10):2425-2437. (Pubitemid 47619746)
6. Contassot E, Kerl K, Roques S, et al. Resistance to FasL and tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in Sézary syndrome Tcells associated with impaired death receptor and FLICE-inhibitory protein expression. Blood. 2008;111(9):4780-4787.
7. Caprini E, Cristofoletti C, Arcelli D, et al. Identification of key regions and genes important in the pathogenesis of Sézary syndrome by combining genomic and expression microarrays. Cancer Res. 2009;69(21):8438-8446.
8. Laharanne E, Oumouhou N, Bonnet F, et al. Genome-wide analysis of cutaneous T-cell lymphomas identifies three clinically relevant classes. J Invest Dermatol. 2010;130(6):1707-1718.
9. Dereure O, Llanos F, Portales P, Clot J, Guilhou JJ. Similar serum levels of soluble forms of Fas and Fas ligand in cutaneous T cell lymphoma and benign lymphocyte-mediated dermatoses: relevancy for defective apoptosis hypothesis. J Invest Dermatol. 2002;118(5):895-896. (Pubitemid 34526558)
10. Nagasawa T, Takakuwa T, Takayama H, et al. Fas gene mutations in mycosis fungoides: analysis of laser capture-microdissected specimens from cutaneous lesions. Oncology. 2004;67(2):130-134. (Pubitemid 39482681)
11. Wu J, Siddiqui J, Nihal M, Vonderheid EC, Wood GS. Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL). Arch Biochem Biophys. In press.
12. Sors A, Jean-Louis F, Pellet C, et al. Down-regulating constitutive activation of the NF-kappaB canonical pathway overcomes the resistance of cutaneous T-cell lymphoma to apoptosis. Blood. 2006;107(6):2354-2363. (Pubitemid 43345555)
13. Jones CL, Wain EM, Chu CC, et al. Downregulation of Fas gene expression in Sézary syndrome is associated with promoter hypermethylation. J Invest Dermatol. 2010;130(4):1116-1125.
14. Avilés A, Nambo MJ, Neri N, et al. Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome. Cancer Biother Radiopharm. 2007;22(6):836-840.
15. Schindler C, Levy DE, Decker T. JAK-STAT signaling: from interferons to cytokines. J Biol Chem. 2007;282(28):20059-20063. (Pubitemid 47099977)
16. Chan H, Bartos DP, Owen-Schaub LB. Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment. Mol Cell Biol. 1999;19(3):2098-2108. (Pubitemid 29098268)
17. Li XR, Chong AS, Wu J, et al. Transcriptional regulation of Fas gene expression by GA-binding protein and AP-1 in T cell antigen receptor.CD3 complex-stimulated T cells. J Biol Chem. 1999;274(49):35203-35210. (Pubitemid 129509578)
18. Kühnel F, Zender L, Paul Y, et al. NFkappaB mediates apoptosis through transcriptional activation of Fas (CD95) in adenoviral hepatitis. J Biol Chem. 2000;275(9):6421-6427. (Pubitemid 30129939)
19. Ivanov VN, Ronai Z, Hei TK. Opposite roles of FAP-1 and dynamin in the regulation of Fas (CD95) translocation to the cell surface and susceptibility to Fas ligand-mediated apoptosis. J Biol Chem. 2006;281(3):1840-1852.
20. Mise-Omata S, Kuroda E, Sugiura T, Yamashita U, Obata Y, Doi TS. The NFkappaB RelA subunit confers resistance to Leishmania major by inducing nitric oxide synthase 2 and Fas expression but not Th1 differentiation. J Immunol. 2009;182(8):4910-4916.
21. Christman JK. 5-Azacytidine and 5-aza-2′-deoxycytidine as inhibitors of DNA methylation: mechanistic studies and their implications for cancer therapy. Oncogene. 2002;21(35):5483-5495. (Pubitemid 34983483)
22. Olsen EA, Rook AH, Zic J, et al. Sézary syndrome: evaluation, immunopathogenesis, literature review of therapeutic options and recommendations for therapy by the United States cutaneous lymphoma consortium (USCLC). J Am Acad Dermatol. In press.
23. Selleri C, Sato T, Del Vecchio L, et al. Involvement of Fas-mediated apoptosis in the inhibitory effects of interferon-alpha in chronic myelogenous leukemia. Blood. 1997;89(3):957-964. (Pubitemid 27121289)
24. Wang XY, Crowston JG, Zoellner H, Healey PR. Interferon-alpha and interferongamma sensitize human tenon fibroblasts to mitomycin-C. Invest Ophthalmol Vis Sci. 2007;48(8):3655-3661. (Pubitemid 351261101)
25. Matikainen S, Sareneva T, Ronni T, Lehtonen A, Koskinen PJ, Julkunen I. Interferonalpha activates multiple STAT proteins and upregulates proliferation-associated IL-2Ralpha, c-myc, and pim-1 genes in human T cells. Blood. 1999;93(6):1980-1991. (Pubitemid 29128500)
26. Gough DJ, Messina NL, Hii L, et al. Functional crosstalk between type I and II interferon through the regulated expression of STAT1. PLoS Biol. 2010;8(4):e1000361.
27. Hoppe RT, Medeiros LJ, Warnke RA, Wood GS. CD8-positive tumor-infiltrating lymphocytes influence the long-term survival of patients with mycosis fungoides. J Am Acad Dermatol. 1995;32(3):448-453.
28. Kim EJ, Hess S, Richardson SK, et al. Immunopathogenesis and therapy of cutaneous T cell lymphoma. J Clin Invest. 2005;115(4):798-812. (Pubitemid 40489380)
29. Mundle SD, Raza A. Defining the dynamics of self-assembled Fas-receptor activation. Trends Immunol. 2002;23(4):187-194. (Pubitemid 34260934)
30. Dzietko M, Boos V, Sifringer M, et al. A critical role for Fas/CD-95 dependent signaling pathways in the pathogenesis of hyperoxia-induced brain injury. Ann Neurol. 2008;64(6):664-673.